October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…
SEOUL, South Korea, Oct. 8, 2025 /PRNewswire/ -- The World Federation of Neurology (WFN) and the Korean Neurological Association (KNA) will…
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin…
PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today at the European Academy of Dermatology and Venereology (EADV)…
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsiesData include an…
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX…
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of…
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase…
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the…